ChemDiv, a California-based global provider of integrated drug discovery solutions, announced on Friday that it is continuing to provide chemistry, computational and clinical pharmacology support to Clywedog Therapeutics.
The company is taking this step as it enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The merged company will operate under the name Clywedog Therapeutics Inc and is expected to be listed on Nasdaq under the ticker CLYD upon closing.
The merged portfolio will concentrate on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.
ChemDiv's ongoing partnerships includes accelerated CMC research, AI-enabled pharmacology, computational modelling and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023-2024.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA